Previous 10 | Next 10 |
– Conference Call and Webcast to Follow at 5:00 p.m. EDT / 2:00 p.m. PDT – Exelixis, Inc. (NASDAQ: EXEL) announced today that its first quarter 2019 financial results will be released on Wednesday, May 1, 2019 after the markets close. At 5:00 p.m. EDT / 2:00 p.m. PDT, ...
̶ Presentation to be webcast on www.exelixis.com ̶ Exelixis, Inc. (NASDAQ: EXEL) today announced that Christopher J. Senner, the company’s Executive Vice President and Chief Financial Officer, and Andrew R. Peters, the company’s Vice President, Str...
Momenta Pharmaceuticals (NASDAQ: MNTA ) initiated with Neutral rating at BTIG Research. More news on: Momenta Pharmaceuticals, Inc., Arcus Biosciences, Inc., Exelixis, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
Exelixis, Inc. (EXEL) Barclays Global Healthcare Conference Call March 13, 2019 9:30 AM ET Company Participants Michael Morrissey - President and Chief Executive Officer Conference Call Participants Geoff Meacham - Barclays Capital Presentation Geoff Meacham Welcome t...
Exelixis, Inc. (EXEL) Cowen & Co. 39th Annual Health Care Conference March 12, 2019, 08:00 AM ET Company Participants Mike Morrissey - President and CEO Conference Call Participants Presentation Unidentified Analyst Okay, good morning everybody and thank you for joi...
Alexion Pharmaceuticals (NASDAQ: ALXN ) initiated with Neutral rating and $135 (6% upside) price target at Guggenheim. More news on: Alexion Pharmaceuticals, Inc., Dermira, Exelixis, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
Gilead Sciences (GILD) has a very tough road ahead after its latest earnings report. The earnings for the fourth quarter were mixed, but the company needs to take drastic action to redeem itself. The revenue may have come in over expectations, but it won't be long until Gilead finds itself i...
Calithera Biosciences ( CALA ) is a good speculative biotech to take a look at. It is using its clinical product CB-839 in combination with already approved therapies to tackle renal cell carcinoma. This approach could be worthwhile, especially since this biotech has two shots on goal to tac...
Updated data from a Phase 1 clinical trial evaluating Calithera Biosciences' ( CALA +4.1% ) glutaminase inhibitor telaglenastat, combined with Exelixis' ( EXEL -2.8% ) Cabometyx (cabozantinib), in previously treated patients with advanced renal cell carcinoma (RCC) showed a positive e...
Exelixis ( EXEL ) announced that it had obtained FDA approval for its drug cabometyx for previously treated patients with hepatocellular carcinoma (liver cancer). This latest approval expands the market opportunity of this drug in the U.S. market. This is good news on top of previous news ...
News, Short Squeeze, Breakout and More Instantly...
– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (Nasdaq: EXEL) announced today that its second quarter 2024 financial results will be released on Tuesday, August 6, 2024 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Ex...
2024-07-11 08:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...